Correspondence  by unknown
gradually decreased over a period of approximately two weeks towards
an OR of one (2).
The possible contribution of airway infections, which occur more
frequently in cold winter months than in summer, have not been listed
by Spencer et al. (1) among the possible explanations for the higher
incidence of AMIs in winter time. Evidence from smaller hospital-
based studies has already previously indicated that an association
between acute chest infections and AMI might exist (3–5). The
pathophysiologic mechanism of such an association is speculative and
could involve changes in circulating clotting factors, an increased risk
for acute rupture of arteriosclerotic plaque during a chest infection, or
a variety of other mechanisms. The role of acute and chronic infections
in the etiology of coronary heart disease and AMI needs to be better
understood; it might be one of the keys towards an explanation why
more AMIs occur in winter than in summer.
CHRISTOPH R. MEIER, PHD, MSC
Boston Collaborative Drug Surveillance Program
Boston University School of Medicine
11 Muzzey Street
Lexington, Massachusetts 02421
References
1. Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal Distribution of Acute
Myocardial Infarction in the Second National Registry of Myocardial Infarction. J Am Coll
Cardiol 1998;31:1226–33.
2. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and
risk of first-time myocardial infarction. Lancet 1998;351:1467–71.
3. Pesonen E, Siitonen O. Acute myocardial infarction precipitated by infectious disease. Am
Heart J 1981;101:512–3.
4. Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with
onset of acute myocardial infarction: prospective investigation of 150 consecutive patients
and matched control patients. Am J Cardiol 1984;53:481–2.
5. Mattila KJ. Viral and bacterial infections in acute myocardial infarction. J Intern Med
1989;225:293–6.
Anticoagulation in Dilated Cardiomyopathy
We read with interest the recent review by Koniaris et al. (1)
concerning anticoagulation in dilated cardiomyopathy. Evidence from
published studies does not convincingly demonstrate the benefits of
anticoagulation in patients with dilated cardiomyopathy. As described
by Koniaris et al., (1) a prospective, randomized clinical trial of
long-term anticoagulation in patients with dilated cardiomyopathy is
feasible. However, studies employing hemostatic markers indicating a
biochemical imbalance between procoagulant and anticoagulant
mechanisms in the blood may be useful to evaluate the appearance of
thrombotic phenomena in these patients (2). By measuring plasma
levels of hemostatic markers, we previously found that, in patients with
dilated cardiomyopathy, plasma levels of fibrinopeptide A and
thrombin-antithrombin III complex, markers of coagulation activation
and thrombin generation, were significantly higher than those in
normal subjects (3). Their levels showed a positive correlation with left
ventricular end-diastolic volume and a negative correlation with frac-
tional shortening of the left ventricle. Although Koniaris et al. (1)
suggested that aspirin monotherapy may be beneficial for risk reduc-
tion of thromboembolism in patients with dilated cardiomyopathy,
plasma levels of platelet factor-4 and beta-thromboglobulin, markers
of platelet activation, were not elevated in these patients compared
with normal subjects. In addition, we previously observed that aspirin
monotherapy suppresses platelet function, but does not affect coagu-
lation activity (4). These findings support the premise that anticoagu-
lant therapy, rather than antiplatelet therapy, is more effective for the
prevention of systemic embolism in patients with dilated cardiomyop-
athy, particularly in those with severe left ventricular enlargement and
dysfunction.
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